| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation for its lead therapeutic candidate, efzofitimod, at the American College of Rheumatology (ACR) Convergence 2023, which is being held November 10 – 15, 2023, in San Diego, CA.
"These data highlight the broad anti-inflammatory potential of efzofitimod in treating immune-driven conditions and strengthen the evidence that neuropilin-2 (NRP2) is an important immune regulator," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Although we remain highly focused on our current clinical development program for efzofitimod in interstitial lung disease (ILD), which includes pulmonary sarcoidosis and systemic sclerosis (SSc or scleroderma)-related ILD, this data provides further evidence regarding the potential broader application of efzofitimod in inflammatory diseases beyond these respiratory conditions."
Details of the presentation appear below. The poster will be available on the aTyr website once presented.
Title: Efzofitimod, a First-in-Class NRP2-Targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Session Title: RA – Treatment Poster II
Session Format: Poster Presentation
Poster Number: 1322
Date and Time: Monday, November 13, 2023, from 9:00 a.m. to 11:00 a.m. PST
Location: Poster Hall, San Diego Convention Center
The poster presents findings from preclinical models of rheumatoid arthritis (RA) and RA-associated ILD (RA-ILD), where NRP2, efzofitimod's binding partner, is known to be expressed on pro-inflammatory synovial macrophages. An animal knockout model for NRP2 demonstrated that NRP2 deficiency exacerbated disease pathology in preclinical models of inflammatory disease. In a model of collagen-induced RA, efzofitimod treatment lowered disease severity and improved remission. Furthermore, in a transgenic mouse model for RA-ILD, treatment with efzofitimod led to a reduction in the number of pro-inflammatory immune cell populations in the lungs and exhibited a noteworthy reduction in RA-induced lung fibrosis. The data indicate a critical role for NRP2 in modulating immune responses and suggest the potential of efzofitimod as a therapeutic intervention for RA-ILD and potentially other immune-mediated diseases.
About Efzofitimod
Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. aTyr is currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD, and in the Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD. These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.
Posted In: LIFE
